Group Leader - Oligo Biology Drug Development
Alyssa Hill completed a Ph.D. in Microbiology in 2017 at the University of Oklahoma, U.S. Her doctoral work focused on the self-assembly of viral prohead RNA and was supported by a Graduate Research Fellowship from the National Science Foundation (NSF). From 2017 to 2023, Alyssa carried out postdoctoral work at Eidgenössische Technische Hochschule (ETH) Zürich, Switzerland. Her projects tackled delivery challenges for nucleic acid therapeutics, particularly small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), with support from the Novartis Research Foundation (FreeNovation Grant), the Swiss National Science Foundation (Spark Grant), and the Roche Innovation Center Copenhagen. Alyssa is a former McNair Scholar committed to achieving higher diversity, equity, and inclusion (DEI) in STEM, with prior awards from DEI initiatives such as Fix The Leaky Pipeline (ETH domain). Alyssa currently is Group Leader - Oligo Biology Drug Development in the Wood Group.
The MOE Modification of RNA: Origins and Widescale Impact on the Oligonucleotide Therapeutics Field
Hill AC. and Hall J., (2023), Helvetica Chimica Acta, 106
Chemically Synthesized, Self-Assembling Small Interfering RNA-Prohead RNA Molecules Trigger Dicer-Independent Gene Silencing.
Hill AC. et al, (2022), Chemistry, 28
Innovative developments and emerging technologies in RNA therapeutics.
Halloy F. et al, (2022), RNA Biol, 19, 313 - 332
Efficient Synthesis of 2'-O-Methoxyethyl Oligonucleotide-Cationic Peptide Conjugates.
Halloy F. et al, (2021), ChemMedChem, 16, 3391 - 3395
Chimeric Flaviviral RNA-siRNA Molecules Resist Degradation by The Exoribonuclease Xrn1 and Trigger Gene Silencing in Mammalian Cells.
Harvey C. et al, (2021), Chembiochem, 22, 3099 - 3106